Over the last few years, we have experienced what some call a golden age for health care, as new medical innovations flourish at an unprecedented rate of growth. Hundreds of billions of dollars1 are being invested into research and development (R&D), once again filling the pipeline with potentially life-changing technologies and treatments.
As we move into this new era of health care, three areas are attracting attention from innovators, inventors and investors: robotic-assisted surgery, computational pathology powered by artificial intelligence (AI) and next-generation genetic sequencing.